Femasys Inc Cash Flow Conversion Efficiency
Femasys Inc cash flow conversion efficiency. Based on the latest financial reports, Femasys Inc (FEMY) has a cash flow conversion efficiency ratio of -0.976x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.94 Million) by net assets ($4.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Femasys Inc (2019–2025)
Cash flow conversion efficiency of Femasys Inc from 2019 to 2025. This chart illustrates how Femasys Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Femasys Inc stock quote for real-time trading data and today's change.
Femasys Inc Cash Flow Conversion Ratio Explained
Femasys Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Femasys Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Femasys Inc ranked by their cash flow conversion efficiency. Also see Femasys Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TR Property Investment Trust plc
LSE:TRY
|
0.023x |
|
Investsmart Group Ltd
AU:INV
|
0.282x |
|
Miliboo SA
PA:ALMLB
|
0.126x |
|
Alexium International Group Ltd
AU:AJX
|
0.625x |
|
YY Group Holding Limited Class A Ordinary Shares
NASDAQ:YYGH
|
-0.093x |
|
Golden Arrow Resources Corp
V:GRG
|
-0.208x |
|
Baru Gold Corp
V:BARU
|
-0.166x |
|
Fusemachines Inc. Common stock
NASDAQ:FUSE
|
1.481x |
Annual Cash Flow Conversion Efficiency for Femasys Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Femasys Inc from 2019 to 2025. Review financial flexibility index of Femasys Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.87 Million | $-18.69 Million | -3.184x | +62.26% |
| 2024-12-31 | $2.30 Million | $-19.44 Million | -8.438x | -1272.75% |
| 2023-12-31 | $18.35 Million | $-11.28 Million | -0.615x | +12.70% |
| 2022-12-31 | $15.24 Million | $-10.73 Million | -0.704x | -133.77% |
| 2021-12-31 | $26.33 Million | $-7.93 Million | -0.301x | +78.46% |
| 2020-12-31 | $3.53 Million | $-4.93 Million | -1.398x | -676.44% |
| 2019-12-31 | $-45.37 Million | $-11.01 Million | 0.243x | -- |
About Femasys Inc
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal pat… Read more